Please use this identifier to cite or link to this item: https://doi.org/10.1111/bph.13191
DC FieldValue
dc.titlePharmacological actions of nobiletin in the modulation of platelet function
dc.contributor.authorVaiyapuri, S
dc.contributor.authorRoweth, H
dc.contributor.authorAli, M.S
dc.contributor.authorUnsworth, A.J
dc.contributor.authorStainer, A.R
dc.contributor.authorFlora, G.D
dc.contributor.authorCrescente, M
dc.contributor.authorJones, C.I
dc.contributor.authorMoraes, L.A
dc.contributor.authorGibbins, J.M
dc.date.accessioned2020-10-23T08:12:13Z
dc.date.available2020-10-23T08:12:13Z
dc.date.issued2015
dc.identifier.citationVaiyapuri, S, Roweth, H, Ali, M.S, Unsworth, A.J, Stainer, A.R, Flora, G.D, Crescente, M, Jones, C.I, Moraes, L.A, Gibbins, J.M (2015). Pharmacological actions of nobiletin in the modulation of platelet function. British Journal of Pharmacology 172 (16) : 4133-4145. ScholarBank@NUS Repository. https://doi.org/10.1111/bph.13191
dc.identifier.issn0007-1188
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/179655
dc.description.abstractBackground and Purpose The discovery that flavonoids are capable of inhibiting platelet function has led to their investigation as potential antithrombotic agents. However, despite the range of studies on the antiplatelet properties of flavonoids, little is known about the mechanisms by which flavonoids inhibit platelet function. In this study, we aimed to explore the pharmacological effects of a polymethoxy flavonoid, nobiletin, in the modulation of platelet function. Experimental Approach The ability of nobiletin to modulate platelet function was explored by using a range of in vitro and in vivo experimental approaches. Aggregation, dense granule secretion and spreading assays were performed using washed platelets. Fibrinogen binding, ?-granule secretion and calcium mobilization assays were performed using platelet-rich plasma and whole blood was used in impedance aggregometry and thrombus formation experiments. The effect of nobiletin in vivo was assessed by measuring tail bleeding time using C57BL/6 mice. Key Results Nobiletin was shown to suppress a range of well-established activatory mechanisms, including platelet aggregation, granule secretion, integrin modulation, calcium mobilization and thrombus formation. Nobiletin extended bleeding time in mice and reduced the phosphorylation of PKB (Akt) and PLC?2 within the collagen receptor (glycoprotein VI)-stimulated pathway, in addition to increasing the levels of cGMP and phosphorylation of vasodilator-stimulated phosphoprotein, a protein whose activity is associated with inhibitory cyclic nucleotide signalling. Conclusions and Implications This study provides insight into the underlying molecular mechanisms through which nobiletin modulates haemostasis and thrombus formation. Therefore, nobiletin may represent a potential antithrombotic agent of dietary origins. © 2015 The British Pharmacological Society.
dc.publisherJohn Wiley and Sons Inc.
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceUnpaywall 20201031
dc.subjectcalcium
dc.subjectcyclic GMP
dc.subjectcyclic nucleotide
dc.subjectfibrinogen
dc.subjectglycoprotein
dc.subjectglycoprotein VI
dc.subjectintegrin
dc.subjectintegrin alpha2beta3
dc.subjectnobiletin
dc.subjectphospholipase C gamma2
dc.subjectphosphoprotein
dc.subjectprotein kinase B
dc.subjectunclassified drug
dc.subjectcalcium
dc.subjectcyclic GMP
dc.subjectfibrinogen
dc.subjectfibrinogen receptor
dc.subjectflavone derivative
dc.subjectnobiletin
dc.subjectprotein kinase B
dc.subjectaggregometry
dc.subjectanimal cell
dc.subjectArticle
dc.subjectbinding affinity
dc.subjectbinding site
dc.subjectbleeding time
dc.subjectblood clotting
dc.subjectcalcium mobilization
dc.subjectcontrolled study
dc.subjectdrug effect
dc.subjectdrug mechanism
dc.subjectdrug potency
dc.subjectenzyme inactivation
dc.subjectenzyme phosphorylation
dc.subjecthomeostasis
dc.subjecthuman
dc.subjecthuman cell
dc.subjectin vitro study
dc.subjectin vivo study
dc.subjectmeasurement
dc.subjectmolecular dynamics
dc.subjectmouse
dc.subjectnonhuman
dc.subjectpriority journal
dc.subjectprotein binding
dc.subjectprotein phosphorylation
dc.subjectsignal transduction
dc.subjectthrombocyte aggregation
dc.subjectthrombocyte function
dc.subjectanimal
dc.subjectblood clotting test
dc.subjectC57BL mouse
dc.subjectcell culture
dc.subjectchemically induced
dc.subjectdrug effects
dc.subjectmetabolism
dc.subjectphysiology
dc.subjectthrombocyte
dc.subjectthrombocyte activation
dc.subjectthrombosis
dc.subjectAnimals
dc.subjectBlood Coagulation Tests
dc.subjectBlood Platelets
dc.subjectCalcium
dc.subjectCells, Cultured
dc.subjectCyclic GMP
dc.subjectFibrinogen
dc.subjectFlavones
dc.subjectHumans
dc.subjectMice, Inbred C57BL
dc.subjectPlatelet Activation
dc.subjectPlatelet Aggregation
dc.subjectPlatelet Glycoprotein GPIIb-IIIa Complex
dc.subjectProto-Oncogene Proteins c-akt
dc.subjectThrombosis
dc.typeArticle
dc.contributor.departmentPHYSIOLOGY
dc.description.doi10.1111/bph.13191
dc.description.sourcetitleBritish Journal of Pharmacology
dc.description.volume172
dc.description.issue16
dc.description.page4133-4145
dc.published.statePublished
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1111_bph_13191.pdf1.39 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons